Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
This consultation develops into a customized treatment strategy based on your personal health goals
Future prospective studies should better characterise rare, delayed, and patient-specific adverse events to support precision-based use of incretin-based therapies
Researchers looked at data from more than 430,000 patients aged 50 and older who took either a GLP-1, sodium-glucose cotransporter 2 inhibitors (SGLT2i), metformin or insulin to manage their diabetes for at least two years
Together, these peptides create a comprehensive anti-aging approach: GHK-CU addresses visible signs of aging through tissue regeneration and skin health, while Epithalon works at the cellular level to support healthspan and biological age optimization
Maximal reductions of at least 20% were seen in 26% of tirzepatide-treated patients, versus 12% of semaglutide-treated patients
